2016
Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosis
Ying L, Zhang F, Pan X, Chen K, Zhang N, Jin J, Wu J, Feng J, Yu H, Jin H, Su D. Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosis. Oncotarget 2016, 5: 86536-86546. PMID: 27852032, PMCID: PMC5349933, DOI: 10.18632/oncotarget.13294.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerComplement component 7NSCLC patientsPotential tumor suppressorOvarian cancerOvarian tissueMultivariate Cox regression analysisLow expressionZhejiang Cancer HospitalIndependent prognostic predictorCox regression analysisPrognosis of patientsAdvanced clinical stageCell lung cancerNormal ovarian tissuesExpression of C7Malignant ovarian tissuesTumor suppressorQuantitative polymerase chain reactionCancer HospitalClinical stagePrognostic predictorLung cancerPolymerase chain reactionPoor differentiation
2014
A Novel Model to Combine Clinical and Pathway-Based Transcriptomic Information for the Prognosis Prediction of Breast Cancer
Huang S, Yee C, Ching T, Yu H, Garmire L. A Novel Model to Combine Clinical and Pathway-Based Transcriptomic Information for the Prognosis Prediction of Breast Cancer. PLOS Computational Biology 2014, 10: e1003851. PMID: 25233347, PMCID: PMC4168973, DOI: 10.1371/journal.pcbi.1003851.Peer-Reviewed Original ResearchUp-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers
Xu F, Zhang H, Su Y, Kong J, Yu H, Qian B. Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers. Clinical And Translational Oncology 2014, 16: 980-985. PMID: 24805982, DOI: 10.1007/s12094-014-1183-9.Peer-Reviewed Original ResearchConceptsFemale lung adenocarcinomaLung adenocarcinomaLung tissueTianjin Medical University Cancer HospitalCorresponding normal lung tissuesCox proportional hazards modelMiR-183-3pProgression-free survivalLymph node metastasisLog-rank testNoncancerous lung tissuesPoor overall survivalLung cancer pathogenesisNormal lung tissuesLung cancer tissuesAdjacent noncancerous tissuesPotent prognostic markerPotential prognostic biomarkerProportional hazards modelT-testStudent's t-testBackgroundLung cancerOverall survivalNode metastasisClinicopathological characteristics
2008
Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women
Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD. Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women. Journal Of The National Cancer Institute 2008, 101: 48-60. PMID: 19116382, PMCID: PMC2639294, DOI: 10.1093/jnci/djn415.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedBiomarkers, TumorBlood GlucoseBody Mass IndexBreast NeoplasmsCase-Control StudiesEstradiolEstrogen Replacement TherapyFemaleHumansHyperinsulinismInsulinInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IMiddle AgedMultivariate AnalysisObesityOdds RatioPostmenopauseProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsStatistics, NonparametricConceptsInsulin-like growth factorLevels of insulinBreast cancerInsulin levelsRisk factorsPostmenopausal womenGrowth factorMultiple breast cancer risk factorsMultivariable Cox proportional hazards modelsWomen's Health Initiative Observational StudyBreast cancer case subjectsBreast cancer risk factorsCox proportional hazards modelHormone therapy useIncident breast cancerIndependent risk factorPostmenopausal breast cancerCancer risk factorsCase-cohort studyProportional hazards modelTotal IGFNondiabetic womenBaseline characteristicsFree IGFProspective cohortHigh miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1
Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Research And Treatment 2008, 117: 131-140. PMID: 18932017, DOI: 10.1007/s10549-008-0219-7.Peer-Reviewed Original ResearchConceptsMiR-21 expressionPoor disease-free survivalHigh miR-21 expressionDisease-free survivalHormone receptor statusHigh miR-21Breast cancerMiR-21Tumor samplesReceptor statusTumor gradeTGF-β1Elevated miR-21 expressionNegative hormone receptor statusProportional hazards regression analysisHigher TGF-β1Lymph node involvementEarly-stage diseaseEarly-stage patientsPrimary breast cancerHazards regression analysisHigh tumor gradeFresh tumor samplesTumor cell growthNode involvementA Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer
Gunter M, Hoover D, Yu H, Wassertheil-Smoller S, Manson J, Li J, Harris T, Rohan T, Xue X, Ho G, Einstein M, Kaplan R, Burk R, Wylie-Rosett J, Pollak M, Anderson G, Howard B, Strickler H. A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer. Cancer Epidemiology Biomarkers & Prevention 2008, 17: 921-929. PMID: 18398032, PMCID: PMC3090086, DOI: 10.1158/1055-9965.epi-07-2686.Peer-Reviewed Original ResearchMeSH KeywordsAgedBody Mass IndexCarcinoma, EndometrioidEndometrial NeoplasmsEstradiolFemaleHumansHypoglycemic AgentsInsulinInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding Protein 3Middle AgedMulticenter Studies as TopicObesityProportional Hazards ModelsProspective StudiesRisk FactorsConceptsInsulin-like growth factorEndometrial cancerEndometrioid adenocarcinomaRisk factorsFree IGFObese womenEstrogen levelsWomen's Health Initiative Observational StudyFree IGF-I levelsIGF-binding protein-3Growth factorBaseline serum specimensIncident endometrial cancerHormone therapy useIGF-I levelsMain histologic typesCase-cohort studyMajor risk factorHigh estrogen levelsTotal IGFPostmenopausal womenHormone therapyProspective cohortRandom subcohortTherapy useAssociations of Insulin-Like Growth Factor (IGF)—I and IGF-Binding Protein—3 with HIV Disease Progression in Women
Strickler H, Fazzari M, Kovacs A, Isasi C, Napolitano L, Minkoff H, Gange S, Young M, Sharp G, Kaplan R, Cohen M, Gunter M, Harris T, Yu H, Schoenbaum E, Landay A, Anastos K. Associations of Insulin-Like Growth Factor (IGF)—I and IGF-Binding Protein—3 with HIV Disease Progression in Women. The Journal Of Infectious Diseases 2008, 197: 319-327. PMID: 18177247, PMCID: PMC3127259, DOI: 10.1086/524848.Peer-Reviewed Original ResearchConceptsHIV disease progressionT-cell count declineCell count declineDisease progressionIGFBP-3Count declineIGF axisHuman immunodeficiency virus (HIV) disease progressionInsulin-like growth factor (IGF) axisHigher IGFBP-3 levelsIGF-Binding Protein-3Low IGF-I levelsInsulin-like growth factorIGFBP-3 levelsUse of HAARTBaseline serum samplesIGF-I levelsIGF-binding proteinsGrowth factor axisHIV pathogenesisLymphocyte numbersSerum levelsThymic growthImmunodeficiency syndromeMultivariable model
2006
Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer
WILEY A, KATSAROS D, FRACCHIOLI S, YU H. Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer. International Journal Of Gynecological Cancer 2006, 16: 210-218. PMID: 16445635, DOI: 10.1111/j.1525-1438.2006.00299.x.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsy, NeedleCarcinomaCohort StudiesDNA MethylationFemaleHumansImmunohistochemistryInsulin-Like Growth Factor Binding Protein 3Multivariate AnalysisNeoplasm StagingOvarian NeoplasmsOvariectomyProbabilityPrognosisProportional Hazards ModelsRetrospective StudiesRisk FactorsSensitivity and SpecificitySurvival RateConceptsIGFBP-3 promoter methylationInsulin-like growth factorIGFBP-3Disease progressionOvarian cancerGrowth factorPromoter methylationEarly-stage ovarian cancerEpithelial ovarian cancer patientsResidual tumor sizeEarly-stage diseaseIGFBP-3 expressionEpithelial ovarian cancerOvarian cancer patientsUseful prognostic markerOvarian cancer progressionIGFBP-3 promoterMethylation-specific polymerase chain reactionIGFBP-3 genePathologic variablesTumor sizeDisease stageCancer patientsPolymerase chain reactionPrognostic marker
2000
Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up
Vassilikos E, Yu H, Trachtenberg J, Nam R, Narod S, Bromberg I, Diamandis E. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clinical Biochemistry 2000, 33: 115-123. PMID: 10751589, DOI: 10.1016/s0009-9120(99)00099-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedDisease-Free SurvivalFluorescent Antibody TechniqueFollow-Up StudiesHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingProportional Hazards ModelsProstatectomyProstate-Specific AntigenProstatic NeoplasmsRecurrenceRegression AnalysisReproducibility of ResultsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsProstate cancer patientsRadical prostatectomySerum PSACancer patientsPSA assaysUltrasensitive prostate specific antigenPre-operative PSAGroup of patientsSerial serum samplesEarly therapeutic interventionSeminal vesicle invasionSurgical margin positivityProstate-specific antigenRegular PSAUltrasensitive PSAPSA increaseMargin positivityClinical stageGleason scorePrognostic indicatorCapsular invasionTissue involvementTumor volumePatientsFast relapse
1999
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination
Yu H, Levesque M, Clark G, Diamandis E. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. British Journal Of Cancer 1999, 81: 490-495. PMID: 10507775, PMCID: PMC2362935, DOI: 10.1038/sj.bjc.6690720.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBiomarkers, TumorBreast NeoplasmsCarcinomaChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDNA ReplicationEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGenes, p53HumansLife TablesLymphatic MetastasisMastectomyMultivariate AnalysisNeoplasm ProteinsNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentPloidiesPrognosisProportional Hazards ModelsProstate-Specific AntigenRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneRiskSensitivity and SpecificitySurvival AnalysisSurvival RateTreatment OutcomeTumor Suppressor Protein p53ConceptsEnzyme-linked immunosorbent assayDisease-free survivalBreast cancer patientsCancer patientsRelative riskCox proportional hazards regression analysisProstate-specific antigen expressionProportional hazards regression analysisReceipt of chemotherapyProgesterone receptor statusSteroid hormone receptor analysisHazards regression analysisRecent clinical evidenceLog-rank testKaplan-Meier plotsOverall survival probabilityHormone receptor analysisPrimary breast carcinomaQuantitative enzyme-linked immunosorbent assayProstate-specific antigenP53 expression statusAssessment of p53Breast cancer prognosisS-phase fractionExpression of p53Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma
Diamandis E, Helle S, Yu H, Melegos D, Lundgren S, Lonning P. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer 1999, 85: 891-898. PMID: 10091767, DOI: 10.1002/(sici)1097-0142(19990215)85:4<891::aid-cncr17>3.0.co;2-k.Peer-Reviewed Original ResearchConceptsPlasma prostate-specific antigenProstate-specific antigenPlasma PSA levelsMetastatic breast carcinomaMegestrol acetatePSA levelsPSA increaseMA treatmentPrognostic valueBreast carcinomaSpecific antigenSecretion of PSAMegestrol acetate treatmentPlasma PSA concentrationProgestin megestrol acetateSensitive immunofluorometric procedureSerial plasma levelsSubset of patientsOverall patient survivalRisk of deathMA withdrawalAlternative regimensPSA changeBetter prognosisDistant metastasis
1996
Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients
Zarghami N, Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Sismondi P, Diamandis E. Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. British Journal Of Cancer 1996, 73: 386-390. PMID: 8562347, PMCID: PMC2074443, DOI: 10.1038/bjc.1996.66.Peer-Reviewed Original ResearchConceptsCK-BB levelsCK-BBTumor cytosolsEstrogen receptor-negative cancersEstrogen receptor-positive tumorsReceptor-positive tumorsBreast cancer patientsRisk of deathReceptor-negative cancersRisk of relapseBreast tumor cytosolsHistological typeClinicopathological variablesPatient survivalPrognostic indicatorTumor stageAggressive tumorsCancer patientsProgesterone receptorUnivariate analysisHigh riskBB groupIsoenzyme levelsPatientsBreast tumors
1995
Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma
Levesque M, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis E. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995, 75: 1327-1338. PMID: 7882283, DOI: 10.1002/1097-0142(19950315)75:6<1327::aid-cncr2820750615>3.0.co;2-p.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCarcinomaFemaleFluorescent Antibody TechniqueHumansMiddle AgedOvarian NeoplasmsPrognosisProportional Hazards ModelsSurvival AnalysisTumor Suppressor Protein p53ConceptsEpithelial ovarian carcinomaOvarian carcinomaMutant p53 proteinResidual tumorHistologic gradeOvarian cancerP53 proteinCancer relapseMutant p53 protein overexpressionLonger disease-free survivalKaplan-Meier survival curvesPostsurgical residual tumorDisease-free survivalEarly-stage diseaseSubset of patientsLow histologic gradeMutant p53 protein accumulationAdvanced-stage cancerDifferent clinical stagesP53-negative tumorsP53-positive tumorsP53 protein overexpressionPoor patient outcomesAnti-p53 antibodiesP53 protein accumulation